Scientific Program

Monday, 27 November


 08:00-17:15

 Registration 

08:50-09.00

Congress Opening
08:50-09:00
Itamar Raz, Israel

09:00-10:30

Session I:
Opening and Keynote Presentations

Chairpersons:

Itamar Raz, Israel
Ralph De Fronzo, USA
  09:00-09:25  
Lessons from High Impact Clinical Trials in 2017
Ralph DeFronzo, USA
 
09:25-09:50
Innovation in Diabetes – What’s Ahead

Francesco Giorgino, Italy 



09:50-10:15
Changing Management Guidelines: Good  Evidence and Bad Evidence
Philip Home, UK

10:15-10:30
Discussion

10:30-11:00

Coffee Break, Networking and Poster Viewing

11:00-12:30

Session II:
Current Regulatory Trends in Diabetes and Drug Development

Chairpersons:
Zan Fleming, USA
David Packham, Australia

  11:00-11:25 
EMA Perspective
Giuseppe Rosano
, UK

11:25-11:50 
US and FDA Perspective 
Zan Fleming, USA

11:50-12:15 
How to Pick and Qualify a CRO
James Nolan, Inclinica, USA

12:15-12:30
Discussion 

 12:30-13:30

Lunch Break, Networking and Poster Viewing

 13:30-15:10

Session III:
Design a Clinical Program for Success

Chairpersons:
Paolo PozzilliItaly
Markolf HanefeldGermany

  13:30-13:50
Convincing Authorities for Innovative Endpoints 
Zan Fleming, USA

13:50-14:10
How New Technologies may Help in Designing Trials in Diabetes
Paolo Pozzilli
, Italy

14:10-14:30
The Role of DSMB (IDMC)
Philip Home, UK

14:30-14: 50
Assessing and Measuring Hypoglycemia 
Avivit Cahn, Israel

14:50-15:10 
Clinical Trials in Older Patients with Frailty Syndrome a Need for Evidence Based Studies
Markolf Hanefeld
, Germany

 15:10-15:30

Coffee Break, Networking and Poster Viewing

 15:30-17:00

Session IV:  
Oral Presentations from Selected Abstracts

Chairpersons:
Philip Home, UK

Andreas Pfützner, Germany
 

15:30-15:40
Pregnancy Outcomes: Effects of Metformin (POEM) Study in Gestational Diabetes   Mellitus - a Long Term Randomized Controlled Trial
Adriaan Kooy, The Netherlands

15:40-15:50
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular  disease, all-cause mortality and deterioration in kidney function in type 2 diabetes
Emilie Hein Zobel, Denmark

15:50-16:00
Hypomagnesaemia in Diabetes patients: Comparison of Serum to Intracellular  Measurement of Responses to Magnesium Supplementation and its role in  Inflammation
Nadia Zghoul, Kuwait

16:00-16:10
Improvement of type 2 diabetes (T2DM) in 250 hypogonadal men with testosterone therapy for 8 years: real-life registry data
Farid Saad, Germany

16:10-16:20
Zygosids - the Novel Family of Complexes for Treatment and Prevention of Type 2   Diabetes
Mordechai (Mottie) Chevion, Vladimir Vinokur, Dror Chevion, Israel

16:20-16:30
Clinical Trials in Middle Income Countries: The Beneficial Role of Networking with Primary Care Physicians
Nebojsa M. Lalic, Serbia

Additional orals will be added


Tuesday, 28 November

 08:30-16:30

Registration 

 09:00-10:30

Session V: Phase 2/3 Studies

Chairpersons:
Eberhard Standl, Germany

Thomas Forst, Germany



  09:00-09:20
Why are Phase 2 Studies so Often Misleading?
Andreas Pfützner, Germany

09:20-09:40
Diabetic Neuropathy and / or  Tools to Quantify Vascular Effects in Phase Studies and / or Biomarkers in Diabetes Studies
Thomas Forst, Profil, Germany

09:40-10:00 
Public Perception of Clinical Trials for Diabetes
Helen Gao and Payal Marathe, Close Concerns, USA

10:00-10:20
Can Real World Evidence Substitute for RCTs to Gain Approval for New Drugs?
Eberhard Standl, Germany

10:20-10:30 
Discussion

 10:30-11:45

Coffee Break, Networking and Guided Poster Walks

11:45-12:45

Session VI:
Cardiovascular Outcome Studies Part 1: What can we Learn from    Retrospective Data

Chairpersons:
John Lachin, USA
Ran Goshen, Israel

  11:45-12:15 
Merits of Observational versus Randomized Clinical Trial Data
John Lachin
, U.S.A

12:15-12:35 
Big Data: Advantages and Shortfalls
Ran Goshen, Israel

12:35-12:45 
Discussion

 12:45-13:45

Lunch Break, Networking and Poster Viewing

 13:45-15:30

Session VII:
Cardiovascular Outcome Studies Part 2: Design, Interpretation and Translation

Chairpersons:
Antonio Ceriello, Italy

Oliver Schnell, Germany



  13:45-14:15 
Next Generation of Diabetes Trials (Round Table)
Neda  RasouliUSA, Zan Fleming, USA

14:15-14:30 
Considerations in the Selection and Analysis of Multiple Outcomes
John Lachin, USA

14:30-14:45
Algorithm Dilemma for the Management of Diabetes.
Antonio Ceriello, Spain

14:45-15:00
Clinical Trials in Diabetic Kidney Disease: The Need for a Personalized Approach 
Hiddo J. Lambers Heerspink, Netherlands 

15:00-15:15
Interpretation and Translation of Cardiovascular studies in clinical  practice
Neda  Rasouli,
USA

15:15-15:30
CVOTs 2017 - what have we learned?
Oliver Schnell,  Germany

 15:30-16:00

Coffee Break, Networking and Poster Viewing

16:00-17:30

Session VIII:
Special National Program to Enhance Drug Development

Chairpersons:
Itamar Raz, Israel
  16:00-16:30
The Importance of IP and How to Select the Right Lawyer and Firm
James Nolan, InClinica, USA
 

16:30

Congress Closing